基于群体药代动力学模型评估前列腺癌患者阿比特龙治疗依从性
本研究基于83名健康志愿者生物等效性研究中1469个阿比特龙血药浓度建立群体药代动力学模型,并用蒙特卡洛模拟生成1000 mg每日一次给药的理论浓度分布。随后将36例前列腺癌患者随访时的实测浓度与模拟分布比较,低于第5百分位或高于第95百分位者判为非依从,结果13例(36%)为非依从。
要点
- 36例前列腺癌患者中13例(36%)被判定为阿比特龙非依从。
核心结论
- 基于群体药代动力学模型与模拟分布比较的依从性评估方法可行,前列腺癌患者阿比特龙治疗非依从率相对较高。
研究设计与样本
- 前瞻性研究,用83名健康志愿者生物等效性研究中1469个阿比特龙血浆浓度建立非线性混合效应群体药代动力学模型。
- 采用蒙特卡洛模拟描述1000 mg每日一次给药的理论药代动力学轮廓分布。
- 对36例接受阿比特龙治疗的前列腺癌患者,将随访实测浓度与模拟分布比较评估依从性。
主要发现
- 36例患者中13例(36%)被归类为非依从。
- 非依从患者观察到不良反应发生趋势更高。
关键数值与推荐
- 阿比特龙实测浓度低于模拟轮廓分布第5百分位或高于第95百分位者判定为非依从。
- 模拟给药方案为阿比特龙1000 mg每日一次。
临床怎么用
- 可借助群体药代动力学模型与模拟分布,用随访实测阿比特龙浓度辅助识别非依从患者。
- 阿比特龙需空腹服用,应关注早餐丰盛程度对依从性的潜在影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Abiraterone treatment requires regular drug intake under fasting conditions due to pronounced food effect, which may impact patient adherence. The aim of this prospective study was to evaluate adherence to abiraterone treatment in patients with prostate cancer. To achieve this aim, an abiraterone population pharmacokinetic model was developed and patients' adherence has been estimated by comparison of measured levels of abiraterone with population model-based simulations. METHODS: A total of 1469 abiraterone plasma levels from 83 healthy volunteers collected in a bioequivalence study were analysed using a nonlinear mixed-effects model. Monte Carlo simulation was used to describe the theoretical distribution of abiraterone pharmacokinetic profiles at a dose of 1000 mg once daily. Adherence of 36 prostate cancer patients treated with abiraterone was then evaluated by comparing the real abiraterone concentration measured in each patient during follow-up visit with the theoretical distribution of profiles based on simulations. Patients whose abiraterone levels were ˂5th or ˃95th percentile of the distribution of simulated profiles were considered to be non-adherent. RESULTS: Based on this evaluation, 13 patients (36%) have been classified as non-adherent. We observed significant association (P = .0361) between richness of the breakfast and rate of non-adherence. Adherent patients reported significantly better overall condition in self-assessments (P = .0384). A trend towards a higher occurrence of adverse effects in non-adherent patients was observed. CONCLUSIONS: We developed an abiraterone population pharmacokinetic model and proposed an advanced approach to medical adherence evaluation. Due to the need for administration under fasting conditions, abiraterone therapy is associated with a relatively high rate of non-adherence.
引用
- Merdita S, Šíma M, Dvořák J, et al. Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model. Br J Clin Pharmacol. 2024. PMID: 38958217. doi:10.1111/bcp.16155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。